Exp Clin Endocrinol Diabetes 2001; 109(8): 389-392
DOI: 10.1055/s-2001-18990
Review

© Johann Ambrosius Barth

Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection

A. Holstein, A. Plaschke, E.-H. Egberts
  • 1st Department of Medicine, Klinikum Lippe-Detmold, Germany
Further Information

Publication History

Publication Date:
13 December 2001 (online)

Summary:

Peripheral lipodystrophy, central adiposity, hyperlipidaemia, insulin resistance, and diabetes mellitus, in varying constellations, are frequent complications of highly active antiretroviral therapy in HIV1-infected patients. The pathogenetic significance of protease inhibitors toxicity has been demonstrated by the partial reversal of metabolic disorders after switching to other antiretroviral regimens. The therapeutic and prognostic implications of these metabolic disorders are not yet clear. The dramatic improvements in the prognosis and quality of life of people with HIV since the introduction of highly active antiretroviral therapy call for evidence based concepts for the management of treatment-related metabolic disturbances.

References

  • 1 Behrens G, Dejam A, Schmidt H, Balks H J, Brabant G, Korner T, Stoll M, Schmidt R E. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.  AIDS. 13 F63-F70 1999; 
  • 2 Behrens G M, Stoll M, Schmidt R E. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?.  Drug Saf. 23 57-76 2000; 
  • 3 Brinkmann K, Smeitink J A, Romijn J A, Reiss P. Mitochondrial toxidity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.  Lancet. 354 1112-1115 1999; 
  • 4 Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.  Diabetes. 50 1378-1388 2001; 
  • 5 Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm D J, Cooper D A. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors.  AIDS. 12 F51-F58 1998; 
  • 6 Carr A, Samaras K, Thorisdottir A, Kaufmann G R, Chisholm D J, Cooper D A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.  Lancet. 353 2093-2099 1999; 
  • 7 Detels R, Munoz A, MacFarlane G, Kingsley L A, Margolick J B, Giorgi J, Schrager L K, Phair J P. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.  JAMA. 280 1497-1503 1998; 
  • 8 Dever L L, Oruwari P A, Figueroa W E, O'Donovan C A, Eng R H. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population.  Ann Pharmacother. 34 580-584 2000; 
  • 9 Fung H B, Kirschenbaum H L, Hameed R. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.  Clin Ther. 22 549-572 2000; 
  • 10 Garg A. Lipodystrophies.  Am J Med. 108 143-152 2000; 
  • 11 Goebel F-D, Westner I. Stoffwechselstörungen und Lipodystrophie. Unerwünschte Wirkungen der antiretroviralen Therapie.  MMW-Fortschr Med 143 (Sonderheft 1) 40-44 2001; 
  • 12 Hadigan C, Corcoran C, Basgoz N, Davis B, Sax D B, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.  JAMA. 284 472-477 2000; 
  • 13 Hadigan C, Meigs J B, Rabe J, D'Agostino R B, Wilson P W, Lipinska I, Tofler G H, Grinspoon S S. Franingham Heart Study: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.  J Clin Endocrinol Metab. 86 939-943 2001; 
  • 14 Martinez E, Conget I, Lorano L, Casamitjana R, Gatell J M. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.  AIDS. 13 805-810 1999; 
  • 15 Murata H, Hruz P W, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy.  J Biol Chem. 275 20251-20254 2000; 
  • 16 Nightingale S L. Public Health Advisory on Protease Inhibitors for HIV Treatment.  JAMA. 278 379 1997; 
  • 17 Palella F J, Delaney K M, Moorman A C, Loveless M O, Fuhrer J, Satten G A, Aschman D J, Holmberg S D. Declining morbidity and mortality among patients with advanced human immunodeficiecy virus infection. HIV Outpatient Study Investigators.  N Engl J Med. 338 79-86 1998; 
  • 18 Schwenk A, Breuer J P, Kremer G, Romer K, Bethe U, Franzen C, Fatkenheuer G, Salzberger B. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study.  Eur J Med Res. 30 443-448 2000; 
  • 19 Segerer S, Bogner J R, Walli R, Loch O, Goebel F D. Hyperlipidemia under therapy with protease inhibitors.  Infection. 27 77-81 1999; 
  • 20 Vigouroux C, Gharakhanian S, Salhi Y, Nguyen T H, Chevenne D, Capeau J, Rozenbaum W. Diabetes, insulin resistance and dyslipoproteinemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).  Diabetes Metab. 25 225-232 1999; 
  • 21 Walli R, Herfort O, Michl G M, Demant T, Jager H, Dieterle C, Bogner J R, Landgraf R, Goebel F D. Treatment with protease inhibitor associated with peripheral insulin resistance and impaired oral glucose tolerance in in HIV-1-infected patients.  AIDS. 12 F167-173 1998; 
  • 22 Walli R, Michl G M, Mühlbayer D, Brinkmann L, Goebel F D. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.  Res Exp Med. 199 253-262 2000; 

Dr. med. Andreas Holstein

1st Department of Medicine

Klinikum Lippe-Detmold

Röntgenstr. 18

D-32756 Detmold

Germany

Phone: + 49-52 31-72 11 71

Fax: + 49-52 31-72 10 35

Email: Andreas.Holstein@t-online.de

    >